Law360, New York (October 29, 2007, 12:00 AM ET) -- A German court has invalidated a Pfizer Inc. patent that covers a key ingredient in popular cholesterol drug Lipitor, the pharmaceutical company said Monday.
The decision by the Federal Patent Court in Munich marked a win for generics drug makers Ranbaxy Laboratories Ltd. and Basics GmbH, which contested the patent for atorvastatin calcium that is set to expire in July 2010.
Pfizer said the revoked patent has no “immediate commercial impact” on the company because neither Ranbaxy nor Basics has received regulatory approval to sell a...
German Court Invalidates Lipitor Patent
To view the full article, take a free trial now.
